A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
about
Profile of brivaracetam and its potential in the treatment of epilepsySynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base[Brivaracetam for add-on treatment in focal epilepsy].Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.A big data approach to the development of mixed-effects models for seizure count data.Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset SeizuresNew developments in the management of partial-onset epilepsy: role of brivaracetam.Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam: First Global Approval.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Will Brivaracetam Help My Patient? Only Time Will Tell.Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus.Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment.Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis.A resurging boom in new drugs for epilepsy and brain disorders.Pharmacological interactions between brivaracetam and ethanol in healthy males.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences.Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany
P2860
Q26776317-10643210-BCC6-4A27-9576-9C5D959E2C0FQ28068507-00DB9837-72E1-4E8D-B224-F8A12E1953AAQ28076065-1D7B3AFB-89ED-44F8-A5BD-47BED1ED482AQ30390285-ED684325-52D5-4842-A6AA-90B5E102225BQ36284727-05FD9879-0F57-40E8-9D32-44FD142411A1Q36332317-9FCB32DA-A215-4FA1-81D0-E0F4EA54EF81Q37113376-7A61E102-42B8-40D2-89B4-E90AD81485E0Q37605300-B6687D0C-0844-4141-BF6E-D7A91B360B8BQ37693757-A3979BB6-EF20-41CB-AD86-DE3F62E5CCB2Q38600989-AD5EB74E-705B-4946-A24C-265478ABD44EQ38614499-1792BA8E-8836-4E19-A182-5FCCE0C847FAQ38621010-BE866B43-CC42-4BA6-84D0-22199BFCB681Q38626838-0C3D4223-0316-483D-8A5A-1AA8DC4D44DDQ38652806-18BD1215-F11B-4070-AA0A-E4C914B447C8Q38743281-01158075-55A3-408B-BC46-003BDDD77925Q38752407-740668F3-C898-4C4B-9635-0337D3FEDDF6Q38844513-F4121B79-96BE-4716-8C64-D48A27C786D7Q38904679-D423A23A-F90B-4094-9460-FD77778B07F5Q38915714-88C9F322-51AD-4A49-A5BD-C61E827319FEQ38922348-D90B0994-10F1-4AE6-9675-984B7F9611B5Q39006241-D2FF4437-1175-4C7A-AF89-19F348BBF698Q39094490-CC70B782-3711-4A1C-8DA8-DCE83C92B5ACQ39707630-94CD98EE-E298-488E-87C2-0EDBC7CE7A3AQ39794501-FEB99DFD-C85F-4E21-84BD-5BCD539A71BCQ39899497-06A4FD5E-14B9-4C93-85A3-E29647E7ABBCQ42317849-CF991210-1085-4CDD-8181-CB114B90CD6DQ46010938-47995C2C-0FD2-426D-91E3-5E58673272CDQ47733662-D1043AEF-79FC-4706-B52F-FD64064ABBBFQ47782948-E6F90E55-BD60-4764-BBA7-B28888B83131Q47836472-68F50637-F14F-491F-B549-9B195ED3F799Q47853821-DD27D280-45ED-464B-A462-AF4E761CEE9FQ47937702-EF42A80E-3ED4-4CD8-8541-AC809684881AQ48093388-BA21FB8B-2948-44BA-A87F-52266046DC6FQ48596485-E3CD8213-4823-43CB-978B-1E15AC7344BEQ49253776-36FA6E36-4F27-4C1C-A27E-03FFF6DDEB6FQ49700507-1C5305B1-1910-4755-B8A7-85F3894F857CQ50075643-741BCF01-81D8-47EE-8E57-CA8694547801Q50183085-C5A182AE-9D5E-4E4A-8528-2262B2BC573DQ53073031-893C15A8-EEB3-42B0-9DCF-990B34E304B9Q57926644-3DB2451D-5B0B-4024-B3C4-7BBAFADA405C
P2860
A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@en
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@nl
type
label
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@en
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@nl
prefLabel
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@en
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@nl
P2093
P2860
P356
P1433
P1476
A randomized, double-blind, pl ...... rolled partial-onset seizures.
@en
P2093
Jimmy Schiemann
John Whitesides
Patrick Kwan
Pavel Klein
Tracy Stalvey
P2860
P304
P356
10.1111/EPI.13212
P577
2015-10-16T00:00:00Z